In a landmark initiative poised to transform the clinical landscape for patients born with single ventricle heart disease, the American Heart Association (AHA) and Additional Ventures have announced a $20 million collaborative investment aimed at fundamentally advancing the care, prediction, and prevention of complications stemming from Fontan circulation. This ambitious program represents a multi-year, multi-phase strategy to confront the lifelong health challenges faced by individuals who rely on the Fontan procedure, a complex surgical intervention that reroutes blood circulation in patients with only one functional heart ventricle.
Single ventricle heart disease, a congenital anomaly affecting approximately 6 in every 10,000 infants born annually in the United States, presents a formidable challenge for modern medicine. These patients are born with a heart defect such that only one ventricle can effectively pump blood, necessitating the Fontan surgical procedure to create a unique circulatory pathway. While this surgery is lifesaving, it introduces a precarious physiological state where systemic venous blood passively flows to the pulmonary arteries without the pumping action from a right ventricle, imposing chronic systemic circulation limitations and organ strain.
Despite the critical importance of the Fontan procedure in survival, the long-term repercussions are profound and pervasive. Patients with Fontan circulation typically endure significant stress not only on their cardiovascular system but also on other vital organ systems including the liver, kidneys, and lungs. This cumulative organ dysfunction is driven by pressure and flow abnormalities inherent in the altered circulatory physiology, leading to progressive complications such as Fontan-associated liver disease, protein-losing enteropathy, and plastic bronchitis, among others.
Current clinical protocols for surveillance and management of patients living with Fontan physiology remain suboptimal. A foundational challenge lies in the inability to detect early signals of decline through existing monitoring techniques, which often results in patients progressing silently towards acute, life-threatening complications. Medical practitioners frequently encounter difficulties in prognosticating disease trajectory and timing optimal interventions, underscoring an urgent need for innovative diagnostic tools and biomarkers.
The program conceived by the AHA and Additional Ventures aims to bridge this critical gap by fostering a coordinated, multidisciplinary approach combining clinical expertise, patient-centered insights, and cutting-edge research. Leveraging the AHA’s expansive research infrastructure, guideline development capabilities, and data coordination mechanisms, alongside Additional Ventures’ deep scientific acumen and strategic philanthropy focused exclusively on single ventricle heart disease, the partnership sets the stage for transformative outcomes.
One of the principal objectives centers on the creation of novel predictive models and monitoring tools that can accurately identify early pathophysiological changes in Fontan circulation patients. This entails integrating advanced imaging modalities, hemodynamic assessments, biomarker discovery, and machine learning algorithms to decipher the complex interplay of cardiovascular and systemic alterations. By harnessing big data analytics and longitudinal patient registries, the initiative aspires to generate robust, personalized risk stratification frameworks.
Additionally, the initiative emphasizes active engagement with patients and caregivers to incorporate lived experiences into research and care pathways. This patient-centered approach acknowledges the heterogeneity of disease manifestation and progression, fostering tailored treatment modalities that reflect individual needs and quality of life considerations. The inclusion of patient voices will be paramount in shaping clinical guidelines and determining meaningful endpoints for therapeutic interventions.
From a scientific standpoint, the collaborative program will explore mechanistic underpinnings of multiorgan dysfunction caused by Fontan physiology. Investigations into the molecular and cellular pathways affected by chronic low cardiac output and venous hypertension are anticipated to reveal novel therapeutic targets. The exploration of fibrosis pathways in liver and lung tissue, renal impairment biomarkers, and inflammatory cascades could pave the way for targeted pharmacologic therapies aimed at mitigating organ damage.
Moreover, a critical aspect of this undertaking is the establishment of an integrated infrastructure to support ongoing research and clinical trials. This includes enhancing existing registries, standardizing data collection methods across institutions, and promoting collaborative networks among cardiologists, hepatologists, pulmonologists, nephrologists, and researchers. The vision is to create a sustainable ecosystem that encourages translational research from bench to bedside, accelerating scientific discoveries into clinical practice.
The six-year timeline for the project is designed to encompass iterative phases, starting with comprehensive assessments of current care paradigms and identification of knowledge voids. Subsequent stages focus on pilot studies to validate innovative diagnostic methodologies, followed by multi-center clinical validation and eventual dissemination of evidence-based guidelines. This phased approach ensures adaptive learning and responsiveness to emerging scientific insights over the duration of the project.
The implications of successfully improving the predictive and preventative care of Fontan circulation patients cannot be overstated. Enhanced surveillance and early intervention have the potential to significantly reduce morbidity and mortality, improve functional capacity, and extend life expectancy. Furthermore, the model generated from this initiative could serve as a blueprint for tackling other complex congenital and chronic cardiovascular diseases that similarly suffer from fragmented care and limited prognostic tools.
Historically, the Fontan procedure marked a paradigm shift by enabling survival of patients who would otherwise face early mortality. However, decades later, the medical community confronts the unintended consequences of this complex physiology. This new initiative underscores a shift from life preservation towards life optimization — transforming reactive management into proactive, precision healthcare tailored to this vulnerable population.
According to Mariell Jessup, the AHA’s chief medical and science officer, the coordinated efforts aim not only to deepen scientific understanding but also to deliver actionable clinical insights that can improve patient outcomes through timely intervention. Similarly, Kirstie Keller, CEO of Additional Ventures, emphasizes the importance of collaboration across the scientific and clinical spectrum to unlock novel solutions and enable a future where lifelong care for Fontan patients is informed by rigorous science and comprehensive monitoring.
In summary, this unprecedented partnership between the American Heart Association and Additional Ventures embodies an essential strategic investment targeting an underserved population afflicted with a rare but devastating congenital heart defect. By mobilizing resources, expertise, and patient engagement, the program charts a bold course to overcome existing barriers, ushering in a new era of innovation that promises to fundamentally alter the prognosis for individuals with Fontan circulation.
The collaborative framework envisaged not only aspires to catalyze immediate improvements in clinical care but also to sow seeds for future research breakthroughs that may ultimately approach curative strategies for single ventricle heart disease. As such, it stands as a testament to the power of focused multidisciplinary collaboration in tackling some of the most formidable challenges posed by congenital cardiovascular disorders.
Subject of Research: Single Ventricle Heart Disease and Fontan Circulation: Advancing Predictive and Preventive Care Strategies
Article Title: American Heart Association and Additional Ventures Launch $20 Million Initiative to Revolutionize Care for Fontan Circulation Patients
News Publication Date: March 30, 2026
Web References:
- American Heart Association on Single Ventricle Defects: https://www.heart.org/en/health-topics/congenital-heart-defects/about-congenital-heart-defects/single-ventricle-defects
- Additional Ventures Website: https://additionalventures.org
- Additional Ventures 2025 Impact Report: https://www.additionalventures.org/wp-content/uploads/2026/03/Additional-Ventures-Impact-Report-2025-FINAL-260317.pdf
References:
[1] Single Ventricle Heart Disease Incidence – ScienceDirect Article: https://www.sciencedirect.com/science/article/abs/pii/S1058981302000425
Keywords: Fontan procedure, single ventricle heart disease, congenital heart defects, cardiovascular disorders, predictive health monitoring, multidisciplinary care, organ dysfunction, imaging biomarkers, patient-centered research
